Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
about
Animal Models and "Omics" Technologies for Identification of Novel Biomarkers and Drug Targets to Prevent Heart FailureArterial stiffness, vascular calcification and bone metabolism in chronic kidney diseaseMagnesium and FGF-23 are independent predictors of pulse pressure in pre-dialysis diabetic chronic kidney disease patients.Combined sequence and sequence-structure based methods for analyzing FGF23, CYP24A1 and VDR genes.FGF-23 is a negative regulator of prenatal and postnatal erythropoiesisCinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism.Rethinking Bone Disease in Kidney Disease
P2860
Q26799838-FD8E1ADC-2F91-47F9-9322-47299108B896Q27024623-01538315-1D15-4E8A-AADD-56E3A6111E8AQ35227631-02DA007E-BF26-40A0-B760-18AD301DA2C6Q36801775-10EDFAD4-72C9-4ACD-8CEA-E99E21045B32Q37683399-E587AF6B-66B8-4762-B6BA-E57FC2383D27Q46921995-55C3160B-A1AC-4962-8BAF-1BED9967C0EEQ59126536-B50C4C5B-D29F-4C15-A63E-D2E8DCBF7B29
P2860
Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Fibroblast growth factor 23 in ...... hts and clinical implications.
@en
Fibroblast growth factor 23 in ...... hts and clinical implications.
@nl
type
label
Fibroblast growth factor 23 in ...... hts and clinical implications.
@en
Fibroblast growth factor 23 in ...... hts and clinical implications.
@nl
prefLabel
Fibroblast growth factor 23 in ...... hts and clinical implications.
@en
Fibroblast growth factor 23 in ...... hts and clinical implications.
@nl
P2093
P2860
P1433
P1476
Fibroblast growth factor 23 in ...... hts and clinical implications.
@en
P2093
Kevan R Polkinghorne
Matthew J Damasiewicz
Nigel D Toussaint
P2860
P304
P356
10.1111/J.1440-1797.2011.01443.X
P577
2011-03-01T00:00:00Z